// App-Quantinova.ai

795 : Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Researchers

Presenter

  • Elliott Vichinsky

Principal Investigators

  • Victor R. Gordeuk

  • Paul Telfer

  • Adlette Inati

  • Margaret Tonda

  • Sarah Gray

  • Irene Agodoa

  • Kenneth I. Ataga

Medical Centers

  • UCSF Benioff Childrens Hospital Oakland, Oakland, CA

  • Comprehensive Sickle Cell Center, Section of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL

  • Barts Health NHS Trust, London, United Kingdom

  • Lebanese American University, Beirut and Nini Hospital, Tripoli, Lebanon

  • Global Blood Therapeutics, South San Francisco, CA

  • The University of Tennessee Health Science Center, Memphis, TN

Locations

  • United States

  • United Kingdom

  • Lebanon

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Volatile organic compounds

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved